Gene-Specific Responses to Exercise in Discordant Twins
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00083837|
Recruitment Status : Completed
First Posted : June 4, 2004
Last Update Posted : July 12, 2016
|Condition or disease|
|Atherosclerosis Cardiovascular Diseases Heart Diseases|
It is well recognized that increased exercise is associated with a number of health benefits, which include decreases in level of obesity and improvement in lipoprotein levels. Differences have been found to exist, however, in individual response to increased exercise, suggesting that genetic factors may be involved in mediating this response. The elucidation of both the specific genes responsible for these differences and the manner by which they interact with increased exercise to influence lipoprotein levels and body weight would contribute significantly to increasing current understanding of the way in which genes and environment operate to determine these characteristics.
As part of the National Runners' Health Study, Dr. Williams and colleagues have identified 1,350 runners who have an identical (MZ) twin. Their recruitment experience shows that an additional 3,120 MZ twins can be located nationally through Runner's World race participation program.Twenty-eight percent of these MZ twin pairs are expected to be discordant for vigorous exercise (sedentary versus running over 10 miles per week) and otherwise eligible for study. The investigators propose to obtain blood for genotyping, detailed lipoprotein subfraction measurements, clinic weights, and proximal (diet record) and long-term (food frequency questionnaire) nutrient intakes in 400 discordant MZ twin pairs to test whether genes affect the lipoprotein and weight response to vigorous exercise. The analyses assume that the sedentary twin represents (theoretically) the body weight and lipoprotein concentrations of the active twin if he or she were sedentary. They will compare the co-twin lipoprotein and weight differences across genotypes after adjusting for diet. Candidate genes will include single nucleotide polymorphisms (SNPs) that have been identified by others to affect lipoproteins, weight, propensity to exercise, or that mitigate the responses of lipoproteins to exercise. They will also compare the co-twin phenotype differences to SNPs and haplotypes that linkage disequilibrium maps suggest characterize most of the major genetic variation for genes affecting lipoprotein metabolism. The lipoproteins will include detailed measurements of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) subclasses using gradient gel electrophoresis. The individual HDL subclasses will also be analyzed after separating the HDL by immunoaffinity chromatography into particles containing both apo A-I and apo A-II (HDL(A-I with A-II)) and those containing apo A-I and no apo A-II (HDL(A-I without A-II)). The design provides the advantages of both the cross-sectional association studies (large phenotypic effects) and the training studies (controlling for genotype) without the self-selection bias of cross-sectional association studies or the small phenotypic response of training studies.
Their first pilot study of 35 pairs of MZ twins revealed a 5.2 mg/dL difference in HDL-cholesterol and a 12 pound weight difference between the active and sedentary twin. By comparison, a major recent training study produced only small average increases in HDL cholesterol (men:l.1 mg/dL; women:l.4 mg/dL) and small decreases in weight (men: 0.9 pounds; women: 0.4 pounds) after 20 weeks of training. The larger effect size of the discordant twin study will provide greater statistical power to detect gene-environment interactions than the training study. DNA samples will be shared with other institutions to cross-validate gene associations identified from training studies or other designs.
|Study Type :||Observational|
|Study Start Date :||May 2004|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||April 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00083837
|OverallOfficial:||Paul Williams||University of California Lawrence Berkeley Lab|